<DOC>
	<DOCNO>NCT00221325</DOCNO>
	<brief_summary>Rituximab first monoclonal antibody receive approval treatment cancer proven lead extended survival administer intravenously treatment patient systemic non-Hodgkin 's lymphoma . We previously demonstrate small fraction Rituximab administer intravenously able cross blood-brain-barrier brain . We test idea direct injection cerebrospinal fluid Rituximab , monoclonal antibody attack kill lymphoma cell , safe use combination methotrexate patient recurrent brain intraocular lymphoma . We also test idea combination rituximab plus methotrexate activity effective treatment recurrent brain intraocular lymphoma .</brief_summary>
	<brief_title>A Safety Study Rituximab Plus MTX Injected Into Cerebrospinal Fluid Treatment Brain Lymphoma</brief_title>
	<detailed_description>Rituximab first monoclonal antibody receive FDA approval treatment cancer . Intravenous administration rituximab demonstrate lead prolongation survival use combination chemotherapy treatment patient systemic non-Hodgkin 's lymphoma . We previously demonstrate small fraction Rituximab administer intravenously able cross blood-brain-barrier brain also previously demonstrate direct intraventricular administration Rituximab able achieve high concentration within cerebrospinal fluid ventricle lumbar sac . We test hypothesis direct intraventricular injection Rituximab combination Methotrexate safe use combination patient recurrent brain intraocular lymphoma . We evaluate safety combination test different dose level Rituximab . We also measure concentration Rituximab intraocular compartment cerebrospinal fluid different time point intraventricular administration determine pharmacokinetics intrathecal Rituximab well potential impact Methotrexate Rituximab distribution . We also test hypothesis intraventricular administration combination rituximab plus methotrexate activity effective treatment recurrent brain intraocular lymphoma .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Intraocular Lymphoma</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>1 . Relapsed , refractory CNS lymphoma , ocular lymphoma , lymphomatous meningitis 2 . Tumors must CD20 + pathologic analysis . 3 . Patients must Ommaya reservoir ( ventricular access device . 4 . Patients may prior intrathecal methotrexate , araC thiotepa must recover reversible toxicity cause prior treatment . 5 . Concurrent systemic chemotherapy allow treatment disease outside meninges exception highdose methotrexate ( &gt; 500 mg/m2/d , highdose araC ( &gt; 2 gm/m2/d ) , highdose thiotepa ( &gt; 300 mg/m2/d ) investigational agent . 6 . Patients must sufficient baseline hematologic function : &gt; 1,500 granulocyte &gt; 50,000 platelets/ul . 7 . Patients must nuclear medicine CSF flow study perform within 30 day treatment show significant obstruction within ventricle . 1 . History whole brain craniospinal irradiation intrathecal chemotherapy &lt; 4 day initiation intraCSF administration rituximab . 2 . Anticipated survival less one month . 3 . HIV infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Phase I Clinical Trial</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>CNS Lymphoma</keyword>
	<keyword>Ocular Lymphoma</keyword>
</DOC>